Imatinib inhibits proliferation of human mesenchymal stem cells and promotes early but not late osteoblast differentiation in vitro

The skeletal effects of the tyrosine kinase inhibitor nilotinib

(2011) Susannah O'Sullivan et al.   BONE

Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro

(2010) S Jönsson et al.   LEUKEMIA

Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate

(2009) Rosa Chung et al.   BONE

Effects of imatinib mesylate in osteoblastogenesis

(2009) Daniele Tibullo et al.   EXPERIMENTAL HEMATOLOGY

Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

(2009) F J Giles et al.   LEUKEMIA

The effects of imatinib on pregnancy outcome

(2008) S. M. Pye et al.   BLOOD

Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

(2008) S. Jonsson et al.   HAEMATOLOGICA

Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals

(2008) Toru Hiraga et al.   INTERNATIONAL JOURNAL OF CANCER

PDGF Receptor β Is a Potent Regulator of Mesenchymal Stromal Cell Function

(2008) Ayano Tokunaga et al.   JOURNAL OF BONE AND MINERAL RESEARCH